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Objective. Cyclophosphamide (CYC) therapy for
systemic lupus erythematosus (SLE), a disease predom-
inantly affecting women of childbearing age, causes an
unacceptably high incidence of irreversible premature
ovarian failure (POF). This study was performed to
evaluate the effectiveness of depot leuprolide acetate, a
synthetic gonadotropin-releasing hormone analog
(GnRH-a), for protection against POF during CYC
therapy.
Methods. Young women with severe SLE treated
in a standardized protocol of monthly intravenous bolus
CYC were offered treatment with GnRH-a (depot leu-
prolide acetate; a 3.75-mg monthly injection during the
standard CYC regimen). Patients treated with GnRH-a
were compared with controls individually matched by
age (5 years) and by cumulative CYC dose (5 gm).
Reproductive status was determined after a minimum
followup of 3 years after CYC therapy. The primary
outcome was time to POF. Paired summary statistical
analyses, Kaplan-Meier survival estimates, and Cox
regression analyses were performed to assess differ-
ences in outcome between groups.
Results. POF developed in 1 of 20 women treated
with GnRH-a (5%) compared with 6 of 20 controls (30%)
matched by age and cumulative CYC dose (matched
odds ratio 0.09, P < 0.05). Kaplan-Meier estimates
demonstrated improved cumulative ovarian protection
over time in the GnRH-a–treated group (P  0.04).
Conclusion. Treatment with GnRH-a during CYC
therapy was associated with a significant reduction of
POF in young women with severe SLE.
Cyclophosphamide (CYC) administration pro-
longs survival and reduces end-organ damage in patients
with severe rheumatic diseases such as systemic lupus
erythematosus (SLE), Wegener’s granulomatosis, and
polyarteritis nodosa. However, treatment with CYC and
other alkylating agents such as chlorambucil is associ-
ated with an unacceptably high incidence of significant
toxicities, including premature ovarian failure (POF;
hypergonadotropic hypogonadism), with consequent ir-
reversible amenorrhea and infertility (1–3). This has
particular significance in the SLE population, since
lupus disproportionately affects women of reproductive
age. In experimental animals, CYC exposure results in
DNA crosslinking in granulosa cells, reduced numbers
of granulosa cells, decreased circulating levels of proges-
terone and estrogen, and ovarian fibrosis (4,5). In hu-
mans, CYC-induced damage to the ovary is generally
regarded as cumulative and irreversible, due in part to
progressive reduction of a limited number of cells (2).
The incidence of POF in both the rheumatic
disease and cancer populations treated with CYC ranges
from 12% to 83% depending on variables such as patient
characteristics and mode of administration. Both age at
initiation of therapy and the cumulative CYC dose are
strong predictors of POF (1–3,6–9). A study of breast
cancer patients showed that the cumulative CYC doses
associated with a 50% incidence of ovarian failure were
20.4 gm, 9.3 gm, and 5.2 gm among women in their 20s,
30s, and 40s, respectively (10).
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In women of reproductive age, pulsatile secretion
of gonadotropin-releasing hormone (GnRH) by the
hypothalamus is required to stimulate pituitary gland
secretion of follicle-stimulating hormone (FSH) and
luteinizing hormone to maintain normal menstrual cy-
cles. Continuous, rather than pulsatile, exposure of the
pituitary gland to GnRH suppresses ovulation, reducing
estrogen and progesterone to prepubertal levels. This
state of reversible “medical castration” can be achieved
with externally administered GnRH analogs (GnRH-a).
GnRH-a administration during chemotherapy may con-
fer ovarian protection due to ovarian suppression or
decline in ovarian blood flow, resulting in decreased
exposure of the ovaries to chemotherapeutic agents (11).
In animals, continuous administration of GnRH-a de-
creases incorporation of tritiated thymidine into granu-
losa cells and prevents CYC-induced ovarian damage
(4,12,13). GnRH analogs may also exert direct protec-
tive effects on the ovary via peripheral GnRH receptors,
which have been documented on human granulosa cells
found in developing and mature follicles (14).
Pilot studies using GnRH-a for ovarian protec-
tion have demonstrated encouraging results (2,15–17).
We report the first study of GnRH-a for ovarian protec-
tion in young women with severe lupus undergoing a
standardized CYC protocol.
PATIENTS AND METHODS
This research was approved by the University of Mich-
igan Institutional Review Board. Written informed consent
was obtained from research participants.
Intravenous CYC (IVCYC) treatment protocol. The
GnRH-a study was nested in a larger IVCYC protocol that has
been ongoing since 1985. All study participants underwent a
standardized IVCYC protocol for the treatment of severe
manifestations of SLE (e.g., nephritis, cerebritis, or vasculitis
judged to require addition of immunosuppressive therapy to a
steroid regimen to prevent end-organ damage). This sequen-
tial therapy protocol consisted of monthly IV boluses of CYC
plus a tapering dosage of daily oral prednisone, as previously
described (18). Following 6 monthly treatments, patients who
achieved satisfactory disease control were switched from IV-
CYC to an additional 2 years of treatment with either azathio-
prine or mycophenolate mofetil to reduce toxicity. Those
patients who did not achieve satisfactory disease control were
treated with an additional 4 monthly boluses of CYC and
reevaluated as above. Depot medroxyprogesterone acetate
(Upjohn, Kalamazoo, MI) 150 mg parenterally every 3 months
was prescribed for contraception during CYC therapy.
GnRH-a protocol for ovarian protection. Participation
in the GnRH-a protocol was offered to consecutive female
SLE patients in whom IVCYC treatment was initiated from
1993 onward. Depot leuprolide acetate (TAP Pharmaceuticals,
Lake Forest, IL), a GnRH agonist, was administered by
injection once per month at a dose of 3.75 mg throughout the
course of CYC treatment. In patients who did not achieve
satisfactory disease control, GnRH-a administration was con-
tinued throughout CYC therapy. In order to avoid CYC
exposure during the initial surge of estrogen, the GnRH-a
injection was timed to occur at least 10 days prior to the
subsequent monthly bolus of IVCYC. In the majority of
patients, initiation of CYC treatment was indicated on an
urgent basis, which did not allow an adequate opportunity to
initiate GnRH-a treatment until 10 days prior to the second
CYC bolus. Following 4 weeks of therapy, patients without
contraindication were given an estradiol patch (estradiol trans-
dermal system, 0.05 or 0.1 mg; Novartis Pharmaceuticals, East
Hanover, NJ) to maintain estrogen at slightly less than early
follicular phase levels and to reduce symptoms of hormonal
withdrawal. The transdermal method was chosen over oral
estradiol add-back therapy because it avoids increased produc-
tion of clotting factors resulting from first-pass hepatic metab-
olism (19).
Study population for analysis of GnRH-a for protec-
tion against POF. Patients. Patients were eligible for this study
if they had a diagnosis consistent with lupus or if they satisfied
the American College of Rheumatology (ACR) criteria for
SLE (20,21), were women of reproductive age, and had an
exacerbation of disease activity requiring treatment with at
least 6 monthly boluses of IVCYC. Patients were excluded
from this analysis if they were age 35 years at the beginning
of CYC treatment or if they were found at baseline to have
symptoms consistent with ovarian failure based on gynecologic
evaluation.
Controls. Controls were randomly selected female SLE
patients in the Michigan Lupus Cohort who had participated in
the IVCYC protocol and fulfilled the above eligibility criteria,
but who had not received GnRH-a. Specifically, the list of
eligible female patients who had received IVCYC but not
GnRH-a was sorted by cumulative CYC dose and patient age
at the beginning of the induction period. For each patient
treated with leuprolide acetate, we matched 1 control patient
within 5 years of age and within 5 cumulative gm of CYC,
using a stratified random sampling procedure without replace-
ment. The matching was performed in a blinded manner by an
investigator (ECS) who was unaware of the reproductive
outcomes of the patients.
Assessment of ovarian function. Annual gynecologic
evaluation is the standard of care implemented at our institu-
tion for SLE patients receiving cytotoxic therapy, particularly
given the increased risk for gynecologic malignancies reported
in this population (22,23). For the purposes of this study, the
preservation of ovarian function was established by the pres-
ence of normal menses and/or conception after treatment with
the IVCYC protocol. Levels of FSH were routinely assessed as
an objective measure of POF in women with oligomenorrhea
or amenorrhea, or when early menopause was otherwise
suspected based on symptoms or gynecologic examination.
Women using cyclic oral contraceptives (OCs) on an ongoing
basis were queried for the presence of symptoms consistent
with menopause (e.g., hot flashes, vaginal dryness, insomnia)
during the pill-free interval. Findings consistent with POF were
subsequently confirmed by documentation of amenorrhea of at
least 12 months’ duration and an FSH level 40 mIU/ml. The
time for the “event” of POF was considered the onset of
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amenorrhea, confirmed after 12 consecutive months. This
approach is consistent with that used for calculation of meno-
pausal age in epidemiologic studies (24). Patient followup was
not continued past age 40 years, which is considered a standard
cutoff age for premature menopause (25). Therefore, cases of
ovarian failure in this study could not be attributed to natural
menopause.
Statistical analysis. Baseline characteristics were sum-
marized for each treatment group and compared using paired
2-tailed t-tests for continuous variables when the underlying
distributions were normal. Fisher’s exact test was used for the
comparison of categorical variables. Odds ratios (ORs) for
matched data were computed based on discordant pairs using
a correction factor of 0.5 per cell to account for a cell with zero
frequency; McNemar’s test for paired data was used to test for
significance. To account for followup time, Kaplan-Meier
survival estimates, stratified by treatment group, were per-
formed to model the cumulative preservation of ovarian
function. Followup time was calculated as the time from CYC
initiation until the first occurrence of one of the following:
development of ovarian failure, loss to followup, death, or
censoring either at age 40 years or at the end of the followup
period. The equality of the survival function across groups was
tested for significance using a Cox regression–based variation
of the log rank test which accounted for the paired nature of
the data. Cox proportional hazards regression was performed
to estimate the hazard ratio of ovarian failure. Data manage-
ment and analysis were performed using Stata 7 (Stata, College
Station, TX).
RESULTS
A total of 40 women (20 treated with GnRH-a
and 20 matched controls) were included in the analysis.
Thirty-nine patients fulfilled the ACR criteria for SLE;
1 patient initially presented with mononeuritis multiplex
and other features characteristic of SLE, but was subse-
quently diagnosed as having systemic vasculitis. The
minimum period of followup was 3.0 years unless ovar-
ian failure developed sooner. The analysis was based on
a total of 287.1 person-years at risk for POF, including
186.9 person-years among controls (median 10.3 years at
risk for POF, range 0.8–16.7 years) and 100.2 person-
years among GnRH-a–treated patients (median 4.6
years at risk for POF, range 0.6–9.3 years). As shown in
Table 1, baseline characteristics were similar between
the 2 groups, particularly for the matching variables of
age at CYC initiation and cumulative CYC dose. The
population was relatively young, with ages ranging from
17 years to 32 years at the start of CYC therapy.
At followup, ovarian failure had developed in 1 of
20 GnRH-a–treated patients (5%) compared with 6 of
20 controls (30%). Based on a matched pairs analysis,
the odds of ovarian failure were significantly lower in the
GnRH-a–treated group (OR 0.09, P  0.05). The single
GnRH-a–treated patient who developed ovarian failure
was older (28.2 years) and received a higher cumulative
CYC dose (33.5 gm) than the corresponding mean
values for the population (24.4 years and 12.9 gm),
representing the 75th and 99th percentiles of age and
dose, respectively. This patient’s matched control was
concordant for development of ovarian failure. Account-
ing for time at risk for ovarian failure, Kaplan-Meier
survival estimates (Figure 1) showed greater cumulative
preservation of ovarian function in the GnRH-a–treated








Age at initiation of CYC, mean
 SD years
23.9  1.0 25.0  0.9
Cumulative dose of CYC, gm 12.9  1.5 12.9  1.5
SLE duration, mean  SD years 3.6  1.2 5.1  1.5
Indication for CYC
Renal 16 (80) 16 (80)
CNS 2 (10) 3 (15)
Other 2 (10) 1 (5)
Race
African American 4 (20) 5 (25)
White 14 (70) 14 (70)
Other 2 (10) 1 (5)
* Except where indicated otherwise, values are the number (%) of
patients. There were no significant differences between the groups.
GnRH-a  gonadotropin-releasing hormone analog; CYC  cyclo-
phosphamide; SLE  systemic lupus erythematosus; CNS  central
nervous system.
Figure 1. Kaplan-Meier survival estimates of time to premature ovar-
ian failure (POF). Tick marks indicate censored observations (i.e., the
final point of followup for patients who did not develop the end point
of POF). GnRH-a  gonadotropin-releasing hormone analog; CYC 
cyclophosphamide.
GnRH-a TREATMENT FOR OVARIAN PROTECTION DURING CYC THERAPY 2763
group than in controls (P  0.04). The median time to
onset of ovarian failure was 4.3 years (interquartile
range 1.2–5.7). Based on Cox regression, the hazard of
developing ovarian failure within 10 years of CYC
initiation in the GnRH-a–treated group was less than
one-tenth that in the control group (hazard ratio 0.09,
95% confidence internal 0.01–0.8). Although it is not
known how many of the women attempted conception
subsequent to CYC therapy, 3 of 20 control patients
(15%) and 7 of 20 GnRH-a–treated patients (35%) had
successful pregnancies following treatment.
There was no statistically significant difference in
adverse events potentially attributable to the study pro-
tocol, including dysfunctional uterine bleeding, deep
venous thrombosis, or new ischemic cardiac events dur-
ing the treatment period (Table 2). However, 2 patients
in the GnRH-a–treated group experienced severe dys-
functional uterine bleeding and severe thrombocytope-
nia. In the GnRH-a–treated group, adverse events not
attributable to the study protocol included a retroperi-
toneal bleed in 1 patient, an episode of hematuria in 1
patient, and development of condylomata and a dystonic
reaction of unknown cause in 1 patient. In the control
group, 1 patient developed superficial thrombophlebitis
and 1 patient developed osteonecrosis.
At long-term followup, there were 5 deaths (4 of
20 patients in the control group and 1 of 20 patients in
the GnRH-a–treated group). All deaths occurred a
minimum of 5.5 years after IVCYC initiation. The
causes of death were myocardial infarction (n  1),
sudden cardiac death (n  3), and sepsis (n  1).
DISCUSSION
In this study of young women treated with
IVCYC for severe manifestations of lupus, administra-
tion of a depot GnRH-a was associated with a significant
reduction of POF. Only 1 of 20 patients in the GnRH-
a–treated group (5%) developed ovarian failure com-
pared with 6 of 20 controls (30%). Notably, the 1 patient
who developed POF in the GnRH-a–treated group was
in the 75th percentile of age and in the 99th percentile of
cumulative CYC dose for our study population, and thus
this patient was at particularly high risk for POF. This is
the first study to analyze a large group of lupus patients
with controls individually matched for age and cumula-
tive dose of CYC, all of whom were undergoing compa-
rable treatment protocols except for GnRH-a use. Our
study was also unique in that it included add-back
estradiol therapy, demonstrating that the protective
effect of GnRH-a is not merely the result of a hypoestro-
genic environment.
Previous studies have demonstrated promising
results for GnRH-a cotherapy, although all have had
important limitations, including heterogeneous chemo-
therapy regimens with varying degrees of cytotoxicity,
limited comparability of control groups with GnRH-a
recipients, and failure to incorporate time at risk for
ovarian failure into their analyses. In 3 studies by
Blumenfeld et al (2,15,16), reduced ovarian injury was
reported in women receiving GnRH-a during chemo-
therapy. The study populations included at least 8 SLE
patients as well as lymphoma and leukemia patients. A
study of Hodgkin’s disease patients receiving standard
MVPP (nitrogen mustard, vinblastine, procarbazine,
prednisone) chemotherapy did not reveal evidence for
ovarian protection among 8 women receiving GnRH-a
cotreatment (intranasal buserelin) compared with 10
controls (26). However, a study of teenage and young
adult patients with lymphoma undergoing various poly-
chemotherapy regimens showed that 100% of 12 pa-
tients receiving GnRH-a cotreatment resumed menstru-
ation compared with none of 4 controls (17).
Our treatment protocol, which uses monthly bo-
lus CYC to achieve remission of lupus nephritis followed
by maintenance therapy with azathioprine or mycophe-
nolate mofetil, is consistent with current sequential
therapy regimens designed to minimize cumulative CYC
exposure in lupus patients (27). Despite the shift in
current treatment patterns toward shorter CYC courses,
a relatively high incidence of ovarian failure persists
(28). Almost one-third of our control patients developed
POF, despite a mean cumulative CYC exposure of 12.9
gm. This contrasts with cumulative doses that have been
routinely administered for rheumatic diseases in the past
(30 gm for a 3-year course of IVCYC for lupus








Dysfunctional uterine bleeding 5 (25)† 2 (10)
Deep venous thrombosis 0 (0) 1 (5)
Depression 3 (15) 2 (10)
Stroke 0 (0) 0 (0)
* Values are the number (%) of patients. There were no significant
differences between the groups. GnRHa  gonadotropin-releasing
hormone analog.
† Includes 2 cases of severe vaginal bleeding associated with thrombo-
cytopenia.
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nephritis [28], and up to 100 gm oral CYC for Wegener’s
granulomatosis [29]).
Our regimen for ovarian protection was well
tolerated. Patients who developed classic symptoms of
hypoestrogenism with GnRH-a therapy, including vagi-
nal dryness and hot flashes (30,31), appeared to respond
to reinstitution of concomitant estrogen replacement
therapy. Women who receive GnRH-a usually develop
amenorrhea with decreased hormone levels within 3–8
weeks (32), with return of menses 6 weeks after the
last subcutaneous injection or 10 weeks after a monthly
depot injection. During the weeks after initiation of
therapy, we found no evidence of SLE flares potentially
attributable to the temporary rise in estrogen.
Of greater concern with GnRH-a therapy is the
accelerated loss of estrogen-dependent trabecular bone,
which has been established in studies of GnRH-a for
treatment of endometriosis (33). The extent to which
restoration of normal bone density occurs after cessation
of therapy is controversial. Two studies of the reversibil-
ity of bone loss resulting from GnRH-a therapy have
shown complete reversal after 4 months (34) and incom-
plete recovery after 12 months (35). These studies
included women with normal baseline bone densities,
and they may not be applicable to patients with lupus or
other connective tissue diseases with a high prevalence
of osteoporosis (36,37).
Measurements of bone mineral density before
and after treatment were not included in this study.
However, to minimize loss of bone mineral density in
our treatment group, and to prevent symptoms of estro-
gen withdrawal, we used a patch to replace estradiol at
or below expected physiologic levels when not otherwise
contraindicated. Quarterly injections of depot medroxy-
progesterone provided reliable contraception and pre-
vented action of unopposed estrogen on the uterus. Use
of antiresorptive agents to protect against bone loss may
be important to consider in patients receiving both
corticosteroids and medications such as leuprolide ace-
tate or depot medroxyprogesterone that decrease estro-
gen levels, particularly if add-back estrogen therapy is
contraindicated.
Despite potential drawbacks associated with
GnRH-a, this strategy is less invasive and costly than
surgical procedures under investigation for fertility pres-
ervation during immunosuppressive therapy, such as
cryopreservation of unfertilized ova or ovarian tissue.
Although promising, oocyte cryopreservation prior to
chemotherapy is considered experimental by the Amer-
ican Society for Reproductive Medicine (38) and should
be performed under the auspices of an institutional
review board. Furthermore, procedures involving ovar-
ian stimulation and oocyte retrieval may be associated
with high risks among SLE patients, in whom blood
dyscrasias and use of immunosuppressive therapy are
common. Cryopreservation of embryos, although well
established and readily available, similarly suffers from
great expense and the added risks of supraphysiologic
estradiol levels with stimulation during an acute flare of
SLE. Moreover, applicability of this approach is limited
by the requirement for patients to have a partner
available and willing to create embryos.
OC pills have also been considered for ovarian
protection during chemotherapy, but supportive data are
lacking. In a widely cited, uncontrolled study of a series
of 6 patients receiving OC pills during standard MVPP
treatment for Hodgkin’s disease, menses resumed in 5
patients; the sixth patient continued taking OC pills after
chemotherapy (39). However, a more recent study com-
paring 31 OC pill–treated patients with 90 matched
non–OC pill–treated patients receiving chemotherapy
showed no difference in the rate of ovarian failure, using
rates of early menopause and pregnancies as outcome
measures (40).
While our study is limited because it was not a
randomized controlled trial, we matched controls to
account for known confounders. It is possible that there
are unknown factors that we could not adjust for, but the
baseline characteristics of the 2 groups appear balanced.
Another concern is that the controls tended to have
begun CYC therapy prior to the availability of the
GnRH-a protocol, and thus they accrued longer fol-
lowup as a group. This was mitigated by using time-to-
event analysis and by including only patients with at least
3 years of followup. Although POF often develops
within this time frame, it will nonetheless be important
to perform further long-term followup on the study
population.
Control patients who received IVCYC at an
earlier time than GnRH-a–treated patients could have
been more severely ill because of the evolution of
clinical practice in our institution toward using this
treatment earlier for renal disease. However, there are
no data to suggest that the severity of lupus activity
affects the development of CYC-induced damage to the
ovary. An additional limitation is that our study was not
designed to assess preservation of ovarian reserve. Be-
cause depot medroxyprogesterone acetate was used in
our protocol, the possibility cannot be excluded that this
agent in combination with GnRH-a contributed to pro-
tection against POF. However, there is no evidence to
suggest that depot medroxyprogesterone acetate would
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be effective in this regard. Lack of an independent effect
of depot medroxyprogesterone for protection against
POF is further substantiated by the high rate of POF in
our controls, despite their use of depot medroxyproges-
terone for contraception.
In this study, treatment with a depot GnRH-a
during CYC therapy was associated with a significant
reduction in the future incidence of ovarian failure
among women with severe SLE. Sequential therapy
consisting of CYC induction followed by maintenance
treatment is becoming the standard of care for severe
lupus nephritis, lending particular relevance to our
findings of ovarian protection in the context of a modern
immunosuppressive protocol with lengthy followup. Fur-
ther investigations are needed to confirm the efficacy
and mechanism of action of GnRH-a for ovarian pro-
tection during CYC therapy. Given the lack of proven
alternatives for preventing CYC-induced ovarian injury,
this intervention has strong potential as a safe, cost-
effective, and easily administered method for ovarian
preservation in women undergoing chemotherapy for a
wide variety of indications.
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